Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial

Assaf P. Oron; Burstein Roy; Laina D. Mercer; Ahmed M. Arzika; Khumbo Kalua; Zakayo Mrango; Sheila K. West; Robin L. Bailey; Travis C. Porco; Thomas M. Lietman

doi:10.4269/ajtmh.18-1004

Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial

Assaf P. Oron, Burstein Roy, Laina D. Mercer, Ahmed M. Arzika, Khumbo Kalua, Zakayo Mrango, Sheila K. West, Robin L. Bailey, Travis C. Porco, Thomas M. Lietman

School of Medicine

Research output: Contribution to journal › Article › peer-review

5 Scopus citations

Abstract

We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.

Original language	English (US)
Pages (from-to)	1295-1300
Number of pages	6
Journal	American Journal of Tropical Medicine and Hygiene
Volume	103
Issue number	3
DOIs	https://doi.org/10.4269/ajtmh.18-1004
State	Published - Sep 2020

ASJC Scopus subject areas

Parasitology
Infectious Diseases
Virology

Access to Document

10.4269/ajtmh.18-1004

Cite this

@article{9017d27599f64ae4829c6fb3b96840bc,

title = "Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial",

abstract = "We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour R{\'e}duire les D{\'e}c{\`e}s avec un Oeil sur la R{\'e}sistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.",

author = "Oron, {Assaf P.} and Burstein Roy and Mercer, {Laina D.} and Arzika, {Ahmed M.} and Khumbo Kalua and Zakayo Mrango and West, {Sheila K.} and Bailey, {Robin L.} and Porco, {Travis C.} and Lietman, {Thomas M.}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 by The American Society of Tropical Medicine and Hygiene",

year = "2020",

month = sep,

doi = "10.4269/ajtmh.18-1004",

language = "English (US)",

volume = "103",

pages = "1295--1300",

journal = "American Journal of Tropical Medicine and Hygiene",

issn = "0002-9637",

publisher = "American Society of Tropical Medicine and Hygiene",

number = "3",

}

TY - JOUR

T1 - Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial

AU - Oron, Assaf P.

AU - Roy, Burstein

AU - Mercer, Laina D.

AU - Arzika, Ahmed M.

AU - Kalua, Khumbo

AU - Mrango, Zakayo

AU - West, Sheila K.

AU - Bailey, Robin L.

AU - Porco, Travis C.

AU - Lietman, Thomas M.

PY - 2020/9

Y1 - 2020/9

N2 - We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.

AB - We examined whether baseline mortality risk, as a function of child age and site, modified the azithromycin mortality-reduction effect in the Macrolide Oraux pour Réduire les Décès avec un Oeil sur la Résistance (MORDOR) clinical trial. We used the Cox proportional hazards model with an interaction term. Three models were examined representing three sources for the baseline-risk covariate: two using sources external to MORDOR and the third leveraging data within MORDOR. All three models provided moderate evidence for the effect becoming stronger with increasing baseline mortality (P = 0.02, 0.02, and 0.07, respectively) at the rate of approximately 6–12% additional mortality reduction per doubling of baseline mortality. Etiological and programmatic implications of these findings are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85090507406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090507406&partnerID=8YFLogxK

U2 - 10.4269/ajtmh.18-1004

DO - 10.4269/ajtmh.18-1004

M3 - Article

C2 - 30734696

AN - SCOPUS:85090507406

SN - 0002-9637

VL - 103

SP - 1295

EP - 1300

JO - American Journal of Tropical Medicine and Hygiene

JF - American Journal of Tropical Medicine and Hygiene

IS - 3

ER -

Effect Modification by Baseline Mortality in the MORDOR Azithromycin Trial

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this